@jbiebhc.bsky.socialWho can benefit from JBI SUMARI❓
✅ Researchers/academics conducting #EvidenceSynthesis
✅ Clinicians translating research into practice
✅ Students learning #SystematicReview methodology
✅ Institutions supporting rigorous, scalable review processes
Conducting a review? ➡️ https://sumari.jbi.global/
@abangelabs.bsky.socialSedentary-break frequency and intensity can change the treatment node, and the conclusions. A 72-trial network shows why dose definition matters. https://www.mattheneus.com/editorial/sedentary-interruption-nma-frequency-intensity-node-taxonomy-2026-10-01 #HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialAcross 29 studies, digital stroke programmes lowered short-term blood pressure, strengthening evidence for post-stroke support. #HTA #EvidenceSynthesis #RWE https://www.mattheneus.com/editorial/pubmed-poststroke-digital-interventions-blood-pressure-meta-analysis-2026-10-01
@abangelabs.bsky.socialA 119-trial Bayesian network can separate supplement signals from ranking certainty, when uncertainty stays visible. https://www.mattheneus.com/editorial/pubmed-dietary-supplements-lower-limb-power-bayesian-network-meta-analysis-2026-10-01 #HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialA 13-trial review maps early analgesia options in acute pancreatitis, highlighting evidence to support treatment decisions. https://www.mattheneus.com/editorial/pubmed-acute-pancreatitis-early-analgesia-randomised-trials-2026-10-01 #HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialEurope’s life-sciences strategy needs an evidence commitment register to turn policy promises into accountable action. https://www.mattheneus.com/editorial/eu-life-sciences-policy-state-register-evidence-commitments-2026-10-05 #HTA #RegulatoryAffairs #EvidenceSynthesis
@cochrane.orgNot all health questions can be answered the same way. This why multiple types of evidence synthesis exist.
Join our webinar, which will provide an overview of the #EvidenceSynthesis family and help you select the most appropriate method for your needs.
@abangelabs.bsky.socialFrance gives durvalumab a minor added-benefit rating in resectable gastric cancer.
#HTA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialPoland questions stand-alone nurse-led chronic wound care in its current design.
#HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialSpecialised formula access expands for pyridoxine-dependent epilepsy.
#HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialGoal Attainment Scaling needs a documented implementation record before it can support credible payer evidence. https://www.mattheneus.com/editorial/goal-attainment-scaling-implementation-record-payer-evidence-2026-10-04 #HTA #EvidenceSynthesis #HealthEconomics
@littview.bsky.socialFull-text screening next, references in Zotero, no PDFs? Our free plugin: select, right-click, and it attaches legal open-access copies via OpenAlex, by DOI, PMID, arXiv ID or title.
@abangelabs.bsky.socialGermany's proposed evidence-potential route could reshape how high-need medicines enter AMNOG assessment. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/g-ba-amnog-reform-qualitative-potential-evidence-route-2026-09-23
@littview.bsky.socialCovidence, Rayyan, Zotero, Elicit, NVivo: not competing answers, different stages of a review. A map of 24 literature review tools across 8 stages, with the overlaps shown.
@abangelabs.bsky.socialAnchored MAIC connects tralokinumab and dupilumab evidence in hand atopic dermatitis. #HTA #MAIC #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/pubmed-tralokinumab-dupilumab-hand-atopic-dermatitis-anchored-maic-2026-10-02
@abangelabs.bsky.socialOne fluoxetine outlier distorted two Lancet networks. A three-analysis reappraisal shows why trial influence matters. https://www.mattheneus.com/editorial/pubmed-fluoxetine-paediatric-depression-outlier-trial-nma-reappraisal-2026-10-02 #HTA #NMA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialDisability equity claims need subgroup cost-effectiveness evidence. Five scenarios show why the details matter. https://www.mattheneus.com/editorial/qaly-disability-subgroup-cost-effectiveness-equity-file-2026-09-28 #HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialAI in lung cancer radiology is advancing faster than its comparative evidence base. #HTA #EvidenceSynthesis https://www.mattheneus.com/editorial/iqwig-lung-cancer-ai-radiology-final-report-evidence-gap-2026-10-01
@abangelabs.bsky.socialFourteen social-science approaches expand how HTA teams assess uncertainty and support implementation. https://www.mattheneus.com/editorial/social-science-uncertainty-method-selection-hta-policy-implementation-2026-10-02 #HTA #EvidenceSynthesis #HealthEconomics
@abangelabs.bsky.socialSweden’s Jaypirca decision shows how unanchored MAIC and Bayesian network analysis can shape CLL access. #HTA #MAIC #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/tlv-jaypirca-pirtobrutinib-cll-unanchored-maic-bayesian-nma-cost-comparison-2026-09-30